What is Dolutegravir (DTG)?

Category: Prescription Drugs

Most popular types: Tivicay Tivicay HIV Post-Exposure Prophylaxis


See also: Abacavir-dolutegravir-lamivudine (ABC/DTG/3TC) Acriptega Triumeq

Dolutegravir is a drug used in combination with other anti-retroviral drugs to treat HIV (Human Immunodeficiency Virus). It is an integrase inhibitor, meaning that it interferes with the replication of the virus in the human body.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 0
Moderate 0
Mild 1
None 9

Commonly reported side effects and conditions associated with Dolutegravir (DTG)

Side effect Patients Percentage
Stomach distention 1


Based on patients currently taking Dolutegravir (DTG)

Dosage Patients Percentage
50 mg daily 5
1 tablet(s) daily 1
50 mg twice daily 1

Why patients stopped taking Dolutegravir (DTG)

Multiple reasons could be selected

Reason Patients Percentage
Other 2
Course of treatment ended 1
See all 3 patients who've stopped taking Dolutegravir (DTG)


Currently taking Dolutegravir (DTG)

Duration Patients Percentage
1 - 6 months 2
2 - 5 years 2
5 - 10 years 3

Stopped taking Dolutegravir (DTG)

Duration Patients Percentage
Less than 1 month 1
6 months - 1 year 1
1 - 2 years 1
Adherence Evaluations Percentage
Always 10
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden Evaluations Percentage
Very hard to take 1
Somewhat hard to take 1
A little hard to take 0
Not at all hard to take 8
Cost per month
Cost per month Evaluations Percentage
$200+ 1
$100-199 0
$50-99 0
$25-49 1
< $25 1
Not specified 7

What people switch to and from

Patients started taking Dolutegravir (DTG) after stopping:

Treatment Patients Percentage
Darunavir (DRV) (Prezista) 3
Ritonavir (RTV, /r) (Norvir) 3
Emtricitabine-Tenofovir disoproxil fumarate (Truvada) 2
Lopinavir-ritonavir (LPV/r) (Kaletra) 2
Abacavir-lamivudine (ABC/3TC) (Epzicom) 1

Show all 9 treatments patients report switching from

Patients stopped taking Dolutegravir (DTG) and switched to:

Treatment Patients Percentage
Triumeq 3
Last updated:
There are no evaluations for Dolutegravir (DTG).